Ganesan A - Search Results

1

Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.

Ruzic D, Petkovic M, Agbaba D, Ganesan A, Nikolic K. Ruzic D, et al. Among authors: ganesan a. Mol Inform. 2019 May;38(5):e1800083. doi: 10.1002/minf.201800083. Epub 2019 Jan 11. Mol Inform. 2019. PMID: 30632697

2

Total synthesis of spiruchostatin A, a potent histone deacetylase inhibitor.

Yurek-George A, Habens F, Brimmell M, Packham G, Ganesan A. Yurek-George A, et al. Among authors: ganesan a. J Am Chem Soc. 2004 Feb 4;126(4):1030-1. doi: 10.1021/ja039258q. J Am Chem Soc. 2004. PMID: 14746465

3

Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue.

Wen S, Carey KL, Nakao Y, Fusetani N, Packham G, Ganesan A. Wen S, et al. Among authors: ganesan a. Org Lett. 2007 Mar 15;9(6):1105-8. doi: 10.1021/ol070046y. Epub 2007 Feb 21. Org Lett. 2007. PMID: 17311393

4

The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.

Yurek-George A, Cecil AR, Mo AH, Wen S, Rogers H, Habens F, Maeda S, Yoshida M, Packham G, Ganesan A. Yurek-George A, et al. Among authors: ganesan a. J Med Chem. 2007 Nov 15;50(23):5720-6. doi: 10.1021/jm0703800. Epub 2007 Oct 24. J Med Chem. 2007. PMID: 17958342

5

Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.

Lecointre B, Narozny R, Borrello MT, Senger J, Chakrabarti A, Jung M, Marek M, Romier C, Melesina J, Sippl W, Bischoff L, Ganesan A. Lecointre B, et al. Among authors: ganesan a. Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748):20170364. doi: 10.1098/rstb.2017.0364. Philos Trans R Soc Lond B Biol Sci. 2018. PMID: 29685969 Free PMC article.

6

QSAR studies on the human sirtuin 2 inhibition by non-covalent 7,5,2-anilinobenzamide derivatives.

Ferreira GM, Magalhães JG, Maltarollo VG, Kronenberger T, Ganesan A, Emery FDS, Trossini GHG. Ferreira GM, et al. Among authors: ganesan a. J Biomol Struct Dyn. 2020 Feb;38(2):354-363. doi: 10.1080/07391102.2019.1574603. Epub 2019 Feb 21. J Biomol Struct Dyn. 2020. PMID: 30789810

7

New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.

Liang L, Wang H, Du Y, Luo B, Meng N, Cen M, Huang P, Ganesan A, Wen S. Liang L, et al. Among authors: ganesan a. Bioorg Chem. 2020 Jun;99:103808. doi: 10.1016/j.bioorg.2020.103808. Epub 2020 Apr 17. Bioorg Chem. 2020. PMID: 32334189

8

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.

Ho TCS, Chan AHY, Ganesan A. Ho TCS, et al. Among authors: ganesan a. J Med Chem. 2020 Nov 12;63(21):12460-12484. doi: 10.1021/acs.jmedchem.0c00830. Epub 2020 Jul 16. J Med Chem. 2020. PMID: 32608981 Review.

9

Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells.

Bulut I, Lee A, Cevatemre B, Ruzic D, Belle R, Kawamura A, Gul S, Nikolic K, Ganesan A, Acilan C. Bulut I, et al. Among authors: ganesan a. Cancers (Basel). 2022 Dec 6;14(23):6014. doi: 10.3390/cancers14236014. Cancers (Basel). 2022. PMID: 36497494 Free PMC article.

10

Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation.

Ruzic D, Ellinger B, Djokovic N, Santibanez JF, Gul S, Beljkas M, Djuric A, Ganesan A, Pavic A, Srdic-Rajic T, Petkovic M, Nikolic K. Ruzic D, et al. Among authors: ganesan a. Pharmaceutics. 2022 Nov 25;14(12):2600. doi: 10.3390/pharmaceutics14122600. Pharmaceutics. 2022. PMID: 36559094 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

751 results

Search Page